BioSpace News Archive

Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board.

Alzamend Neuro, Inc. announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for the initiation of study AL001-MDD01, a Phase IIA clinical study of AL001 for treatment of patients with MDD.

VBI Vaccines Inc. announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma patients, were highlighted in a poster presentation at the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology, held on Friday, November 17, 2023.

BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada.

Hyperfine, Inc. announced that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America 2023 Annual Meeting in Chicago.

RION, a leading clinical-stage regenerative medicine company, announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense on a $2.4M grant awarded from the Department of Defense.

BioTech Medics, Inc. is pleased to announce that the Company continues to build the fundamental substructure that will enhance our ability to raise capital to position the organization in a competitive advantage with its calcium carbonate assets to enhance BMCS as a substantial publicly traded firm in this sector.

Rakovina Therapeutics Inc. announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to its Scientific Advisory Board.

Medicovestor, Inc, a privately-held biopharmaceutical company focused on the development of novel antibody drug-conjugate therapies, proudly announces the successful completion of its oversubscribed Seed financing round.

Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).